Company Encyclopedia
View More
name
Sensei Biotherapeutics
SNSE.US
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.
1.875 T
SNSE.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

    BOSTON, Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc. ( Nasdaq: SNSE ) , a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025.

    GlobeNewswire·
    US
    SNSE
    -12.13%
    GlobeNewswire·
    US
    SNSE
    -12.13%

    Sensei Biotherapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    SNSE
    -12.13%
    LB filings·
    US
    SNSE
    -12.13%

    Sensei Biotherapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    SNSE
    -12.13%
    LB filings·
    US
    SNSE
    -12.13%

    Sensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%

    Sensei Biotherapeutics reported a Q3 net loss of $4.6 million, down from $7.3 million last year. The company reduced its workforce by 65% to preserve cash amid a strategic review, which includes exploring asset sales and potential mergers. R&D expenses decreased to $2.5 million from $4.6 million. The average analyst rating for the company is "buy."

    Reuters·
    US
    SNSE
    -12.13%
    Reuters·
    US
    SNSE
    -12.13%

    Sensei to ditch its lead candidate and cut workforce amidst strategic review

    Sensei Biotherapeutics is discontinuing its lead clinical-stage asset, solnerstotug, and cutting its workforce as part of a strategic review aimed at maximizing shareholder value. Despite positive Phase I data, the company is exploring options including a sale or merger. This decision follows previous workforce reductions and setbacks in its clinical pipeline. CEO John Celebi emphasized the need to preserve cash and shareholder value during this transition.

    Pharmaceutical Technology·
    US
    SNSE
    -12.13%
    Pharmaceutical Technology·
    US
    SNSE
    -12.13%